Elenitoba-Johnson KSJ - Search Results

1

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.

Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL. Aggarwal C, et al. JAMA Oncol. 2019 Feb 1;5(2):173-180. doi: 10.1001/jamaoncol.2018.4305. JAMA Oncol. 2019. PMID: 30325992 Free PMC article.

2

Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis.

Till JE, Black TA, Gentile C, Abdalla A, Wang Z, Sangha HK, Roth JJ, Sussman R, Yee SS, O'Hara MH, Thompson JC, Aggarwal C, Hwang WT, Elenitoba-Johnson KSJ, Carpenter EL. Till JE, et al. Among authors: elenitoba johnson ksj. J Mol Diagn. 2021 Nov;23(11):1545-1552. doi: 10.1016/j.jmoldx.2021.08.007. Epub 2021 Aug 25. J Mol Diagn. 2021. PMID: 34454115 Free PMC article.

3

Precision Medicine for Diffuse Large B-cell Lymphoma.

Lim MS, Elenitoba-Johnson KS. Lim MS, et al. Clin Cancer Res. 2016 Jun 15;22(12):2829-31. doi: 10.1158/1078-0432.CCR-16-0232. Epub 2016 Mar 17. Clin Cancer Res. 2016. PMID: 26988247

4

Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma.

Udager AM, McHugh JB, Betz BL, Montone KT, Livolsi VA, Seethala RR, Yakirevich E, Iwenofu OH, Perez-Ordonez B, DuRoss KE, Weigelin HC, Lim MS, Elenitoba-Johnson KS, Brown NA. Udager AM, et al. J Pathol. 2016 Aug;239(4):394-8. doi: 10.1002/path.4750. Epub 2016 Jul 1. J Pathol. 2016. PMID: 27234382 Free article.

5

Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas.

Udager AM, McHugh JB, Goudsmit CM, Weigelin HC, Lim MS, Elenitoba-Johnson KSJ, Betz BL, Carey TE, Brown NA. Udager AM, et al. Ann Oncol. 2018 Feb 1;29(2):466-471. doi: 10.1093/annonc/mdx736. Ann Oncol. 2018. PMID: 29145573 Free PMC article.

6

Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis.

Brown NA, Elenitoba-Johnson KSJ. Brown NA, et al. Curr Opin Pulm Med. 2018 May;24(3):281-286. doi: 10.1097/MCP.0000000000000470. Curr Opin Pulm Med. 2018. PMID: 29470255 Review.

7

Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.

Habiel DM, Krepostman N, Lilly M, Cavassani K, Coelho AL, Shibata T, Elenitoba-Johnson K, Hogaboam CM. Habiel DM, et al. Oncotarget. 2016 Dec 13;7(50):83514-83529. doi: 10.18632/oncotarget.13158. Oncotarget. 2016. PMID: 27835864 Free PMC article.

8

Novel insights into the pathogenesis of T-cell lymphomas.

Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ. Van Arnam JS, et al. Blood. 2018 May 24;131(21):2320-2330. doi: 10.1182/blood-2017-11-764357. Epub 2018 Apr 17. Blood. 2018. PMID: 29666117 Free article. Review.

9

Functional profiling to improve therapy in TCL.

Elenitoba-Johnson KSJ. Elenitoba-Johnson KSJ. Blood. 2019 Feb 7;133(6):504-506. doi: 10.1182/blood-2018-12-889741. Blood. 2019. PMID: 30733202 Free article. No abstract available.

10

Activating FGFR2-RAS-BRAF mutations in ameloblastoma.

Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL. Brown NA, et al. Clin Cancer Res. 2014 Nov 1;20(21):5517-26. doi: 10.1158/1078-0432.CCR-14-1069. Epub 2014 Jul 3. Clin Cancer Res. 2014. PMID: 24993163

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page